![]() | Only 14 pages are availabe for public view |
Abstract Background; Inflammatory bowel diseases (IBDs) are idiopathic diseases caused by the destruction of the mucosa gastrointestinal tract by the mucosal immune system. The main types of inflammatory bowel disease are Crohn’s disease (CD) and ulcerative colitis (UC). Aim and objectives; To determine the serum concentrations of visfatin in newly diagnosed IBD patients, to evaluate its role in the diagnosis of IBD, and to correlate it with disease activity and colonoscopic findings . Subjects and methods; This was a case-control study that was conducted in a gastroenterology outpatient clinic,Alex Fever Hospital over 90 studied subjects were divided into three groups. Results; As regards serum visfatin, there was a statistically significant difference between Crohn’s disease, ulcerative colitis, and control groups (p2<0.001). The Post Hoc test revealed that the Crohn’s disease group had a significantly higher serum visfatin level (3.7 ± 2.43) than the control group (1.26 ± 0.79), (p3<0.001). Moreover, ulcerative colitis had a significantly higher serum visfatin level than the control group with means of 4.04 ± 2.19 and 1.26 ± 0.79 respectively, (p<0.001). However, there was no statistically significant difference between Crohn’s disease and ulcerative colitis with means of 3.7 ± 2.43 and 4.04 ± 2.19 respectively (p1=0.441).there were no significantdifferences between Crohn’s disease and Ulcerative colitis as regards serum visfatin with meansof 3.7 ± 2.43 and 4.04 ± 2.19 respectively. there was no significant difference between Crohn’s disease (A2 and A3) as regards fecal calprotectin and serum visfatin.there was no significant difference between Crohn’s disease (L1 and L3) as regards fecal calprotectin and serum visfatin. |